Loading...
India's cyclophosphamide imports from GERMANY total $3.6K across 3 shipments from 2 foreign suppliers. E-PHARM LIMITED leads with $2.1K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include EXTROVIS PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for cyclophosphamide — a concentrated sourcing relationship with select suppliers from GERMANY.
E-PHARM LIMITED is the leading Cyclophosphamide supplier from GERMANY to India, with import value of $2.1K across 2 shipments. The top 5 suppliers — E-PHARM LIMITED, E PHARM LIMITED — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | E-PHARM LIMITED | $2.1K | 2 | 58.7% |
| 2 | E PHARM LIMITED | $1.5K | 1 | 41.3% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | EXTROVIS PRIVATE LIMITED | $3.6K | 3 | 100.0% |
GERMANY → India trade corridor intelligence
The Germany to India corridor for pharmaceutical imports, including Cyclophosphamide formulations, is currently stable:
1. Port Congestion: Major ports like Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently with minimal congestion.
2. Freight Rates: Freight rates have remained consistent over the past year, with no significant fluctuations.
3. Currency Exchange: The exchange rate between the Euro and the Indian Rupee has been relatively stable, with minor variations.
These factors contribute to a reliable and predictable supply chain for pharmaceutical imports from Germany to India.
India's recent import policies, including the Production Linked Incentive (PLI) scheme, aim to boost domestic manufacturing and reduce import dependency:
1. PLI Scheme Impact: The PLI scheme offers incentives to domestic manufacturers, encouraging the production of pharmaceutical formulations locally.
2. Import Substitution Policies: There is a concerted effort to develop domestic capabilities to manufacture formulations that are currently imported, including Cyclophosphamide.
3. Reducing Import Dependency: While the PLI scheme and import substitution policies aim to reduce reliance on imports, certain specialized formulations may continue to be sourced from countries like Germany due to technological and quality considerations.
These initiatives reflect India's commitment to enhancing self-reliance in the pharmaceutical sector.
The trade relationship between India and Germany is robust, with ongoing efforts to strengthen pharmaceutical trade:
1. Free Trade Agreement (FTA) Negotiations: Discussions are ongoing to establish an FTA between India and the European Union, which would include Germany, aiming to reduce trade barriers and enhance market access.
2. Mutual GMP Recognition: Both countries recognize each other's Good Manufacturing Practices, facilitating smoother regulatory processes for pharmaceutical imports.
3. Pharma Trade Facilitation: Joint initiatives are in place to streamline customs procedures, improve logistics, and promote collaboration between Indian and German pharmaceutical companies.
These efforts underscore the strong bilateral trade relations and the potential for growth in pharmaceutical trade between the two nations.
The estimated landed cost for importing finished pharmaceutical formulations containing Cyclophosphamide from Germany to India is as follows:
1. FOB (Free on Board) from Germany: $2,100
2
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041) into India, the following regulatory requirements must be met:
1. Import License: An Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) is mandatory. Additionally, an import license from the Central Drugs Standard Control Organization (CDSCO) is required for each consignment.
2. CDSCO Registration: The product must be registered with CDSCO. This involves submitting Form 40 or 41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and stability data.
3. Drug Controller General of India (DCGI) Approval: The DCGI must approve the product, ensuring it meets safety, efficacy, and quality standards.
4. No Objection Certificate (NOC): If the product is manufactured in a Special Economic Zone (SEZ), an NOC from the SEZ authority is required for transfer to the Domestic Tariff Area (DTA).
The registration process typically takes 6–12 months, depending on the completeness of the application and compliance with regulatory requirements.
Imported finished pharmaceutical formulations containing Cyclophosphamide must undergo stringent quality testing to ensure compliance with Indian standards:
1. CDSCO-Approved Laboratory Testing: Each batch must be tested in a laboratory approved by CDSCO. The testing includes verification of identity, purity, strength, and quality.
2. Certificate of Analysis (CoA): A CoA from the manufacturer, detailing the results of the quality tests, must accompany each shipment.
3. Stability Data: Stability studies must be conducted in accordance with International Council for Harmonisation (ICH) guidelines, specifically for Zone IV conditions, to ensure the product's stability under Indian climatic conditions.
4. Indian Pharmacopoeia Standards: The product must comply with the standards set forth in the Indian Pharmacopoeia.
Upon arrival, customs drug inspectors perform port inspections to verify compliance with these requirements.
Recent developments in India's import policies affecting finished pharmaceutical formulations containing Cyclophosphamide include:
1. Mandatory Import Registration and License: As of April 2025, the CDSCO has mandated that all imported medicines, including finished formulations, must obtain import registration and licenses to prevent the sale of unapproved or illegal medicines in the Indian market.
2. Streamlined Procedures for SEZ to DTA Transfers: The CDSCO has introduced procedures to streamline the transfer of drugs manufactured in Special Economic Zones (SEZs) to the Domestic Tariff Area (DTA), ensuring that these drugs meet quality, safety, and efficacy standards.
3. Enhanced Regulatory Scrutiny: There has been an increase in regulatory scrutiny of imported pharmaceutical products, with a focus on ensuring compliance with Indian standards and preventing the entry of substandard or counterfeit drugs.
These changes aim to strengthen the regulatory framework governing pharmaceutical imports and enhance the safety and efficacy of medicines available in the Indian market.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished pharmaceutical formulations containing Cyclophosphamide due to several factors:
1. Patented and Branded Formulations: Certain patented or branded formulations are not manufactured domestically, necessitating imports to meet patient needs.
2. Specific Dosage Forms: Specialized dosage forms, such as injectable solutions or novel delivery systems, may not be produced locally, leading to reliance on imports.
3. Domestic Capacity vs. Import Dependency: While India has a robust pharmaceutical manufacturing sector, the capacity to produce certain complex formulations may be limited, resulting in import dependency.
The market size for Cyclophosphamide formulations in India is substantial, with imports contributing to meeting the therapeutic demands of oncology patients.
The import duty structure for finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041) in India is as follows:
1. Basic Customs Duty (BCD): 10%
2. Social Welfare Surcharge (SWS): 10% of BCD, amounting to 1%
3. Integrated Goods and Services Tax (IGST): 18% on the total of CIF (Cost, Insurance, and Freight) value plus BCD and SWS
4. Anti-Dumping Duty: Currently, there is no anti-dumping duty imposed on Cyclophosphamide formulations.
5. Exemption Notifications: No specific exemption notifications are applicable for Germany-origin products under HS Code 30049041.
The total landed duty percentage is approximately 29%, comprising BCD, SWS, and IGST.
India sources finished pharmaceutical formulations containing Cyclophosphamide from Germany due to several competitive advantages:
1. Patents and Specialized Dosage Forms: German manufacturers often hold patents for innovative formulations and specialized dosage forms that are not available from other suppliers.
2. Quality Assurance: Germany is renowned for its stringent quality control measures, ensuring high-quality products that meet international standards.
3. Regulatory Compliance: German pharmaceutical companies adhere to Good Manufacturing Practices (GMP) and other regulatory requirements, facilitating smoother import processes.
Other suppliers, such as China and the United States, also export Cyclophosphamide formulations to India. However, Germany's reputation for quality and innovation positions it favorably in the Indian market.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Cyclophosphamide suppliers from GERMANY to India include E-PHARM LIMITED, E PHARM LIMITED. The leading supplier is E-PHARM LIMITED with import value of $2.1K USD across 2 shipments. India imported Cyclophosphamide worth $3.6K USD from GERMANY in total across 3 shipments.
India imported Cyclophosphamide worth $3.6K USD from GERMANY across 3 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Cyclophosphamide sourced from GERMANY include EXTROVIS PRIVATE LIMITED. The largest buyer is EXTROVIS PRIVATE LIMITED with $3.6K in imports across 3 shipments.
The total value of Cyclophosphamide imports from GERMANY to India is $3.6K USD, across 3 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Verified Shipments
2 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists